

## Cancer Immunotherapies: Biology, Therapeutic Approaches, and Immune Related Safety Assessments

Dates: April 9-10, 2019

Location: Genentech, South San Francisco, CA

### DRAFT AGENDA

8:30 AM – 9:00 AM	Introduction and overview <ul style="list-style-type: none"><li>• Objectives of the course/Goals over the 2 day course</li><li>• Brief overview of the various topics/modules that will be covered</li></ul>	
Cancer Immunotherapies Overview: Biology and Approaches		
9:00 AM – 10:00 AM	General concepts of interplay between tumors and immunity	<i>Keith Bajhat, Pfizer</i>
10:00 – 10:15 AM	Break	
10:15 AM – 11:15AM	The immune system in the tumor microenvironment vs. normal tissue	<i>Shannon Turley, Genentech</i>
11:15 AM – 12:15PM	Immunotherapy platforms/modalities overview	<i>Keith Bajhat, Pfizer</i>
12:15 PM – 1:15 PM	Lunch	
1:15 PM – 2:15 PM	Regulatory perspective on key cancer immunotherapy related toxicities	<i>Whitney Helms, US FDA</i>
2:15 PM – 3:15 PM	Overview: toxicity as a result of immunomodulation	<i>Rafael Ponce, Spark Therapeutics</i>
3:15 PM – 3:30 PM	Break	
3:30 PM – 5:00 PM	Toxicities associated with modulation of the innate immunity	<i>Tracey Papenfuss, Charles River Labs</i>

**Day 2: 10 April 2019**

Toxicities associated with activation of the adaptive immunity

8:30 AM – 9:15 AM	Cytokine release syndrome	<i>Hervé Lebrech, Amgen</i>
9:15 AM – 10:00 AM	Vascular leak syndrome	<i>Jule Gust, Seattle Children's Hospital</i>
10:00 AM – 10:15AM	Break	
10:15 AM – 11:00 PM	Neurotoxicity	<i>Conrad Liles, U. of Washington</i>
11:00 AM – 11:45 PM	Cardiovascular and respiratory toxicities	<i>Rafael Ponce, Spark Therapeutics</i>
11:45 PM – 12:30 PM	Lunch	

**Session 3: Toxicities associated with blockade of immunosuppressive/check point mechanisms**

12:30 PM – 1:30 PM	CPI-induced immune related adverse events / autoimmunity	<i>Isabella Glitza-Oliva, MD Anderson</i>
1:30 PM – 2:15 PM	CPI-related pregnancy risks	<i>Curtis Maier, GlaxoSmithKline</i>
2:15 PM – 2:30 PM	Break	
2:30 PM – 3:30 PM	Case-studies: Toxicities associated with blockage of negative regulators of T cells	<i>Rod Prell, Genentech Marc Pallardy, University of Paris, Sud</i>
3:30 PM – 4:30 PM	Toxicities associated with synergistic pathways/ computational toxicology modeling	<i>Valeriu Damian, GlaxoSmithKline Loveleena Bansal, GlaxoSmithKline</i>